Education
About Us
Working with TipRanks
Follow Us
Sensus Healthcare, Inc. (SRTS)
:SRTS
SRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $9.33
Previous CloseN/A
Volume208.66K
Average Volume (3M)175.60K
Market Cap
$53.78M
Enterprise Value$55.79M
Total Cash (Recent Filing)$19.07M
Total Debt (Recent Filing)$654.00K
Price to Earnings (P/E)48.7
Beta1.00
Next Earnings
Nov 06, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding16,440,037
10 Day Avg. Volume325,056
30 Day Avg. Volume175,600
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit2.52
Enterprise Value/Ebitda19.43
Forecast
1Y Price Target
$7.10Price Target Upside107.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Partnerships And CollaborationsThe company engaged Radiology Oncology Systems as a primary distribution partner to hospital-based radiation oncology departments and freestanding oncology centers nationwide.
Product Demand And Sales GrowthSensus anticipates surpassing 900 capital sales during Q2, with expectations to reach 1,000 in the next 12 months, suggesting strong sales growth.
Reimbursement And Policy AdjustmentsMedicare proposed a physician fee schedule that would significantly increase reimbursement for the delivery of a code of SRT.
Bears Say
Market Perception And ValuationSome investors perceive Sensus and SkinCure as competitors due to similarities in their business models, potentially affecting Sensus' current valuation.
Regulatory ChallengesA proposed Local Coverage Determination to limit the reimbursement for ultrasound has a negative impact on topline sales since May 2025.
Revenue And Financial PerformanceTotal revenue was $7.3M, representing 21% YoY decline and missing our projection of $8.3M.
Sensus Healthcare News
SRTS FAQ
What was Sensus Healthcare, Inc.’s price range in the past 12 months?
Sensus Healthcare, Inc. lowest stock price was $3.03 and its highest was $9.33 in the past 12 months.
What is Sensus Healthcare, Inc.’s market cap?
Sensus Healthcare, Inc.’s market cap is $53.78M.
When is Sensus Healthcare, Inc.’s upcoming earnings report date?
Sensus Healthcare, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.
How were Sensus Healthcare, Inc.’s earnings last quarter?
Sensus Healthcare, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0.026 by -$0.086.
Is Sensus Healthcare, Inc. overvalued?
According to Wall Street analysts Sensus Healthcare, Inc.’s price is currently Undervalued.
Does Sensus Healthcare, Inc. pay dividends?
Sensus Healthcare, Inc. does not currently pay dividends.
What is Sensus Healthcare, Inc.’s EPS estimate?
Sensus Healthcare, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Sensus Healthcare, Inc. have?
Sensus Healthcare, Inc. has 16,440,037 shares outstanding.
What happened to Sensus Healthcare, Inc.’s price movement after its last earnings report?
Sensus Healthcare, Inc. reported an EPS of -$0.06 in its last earnings report, missing expectations of $0.026. Following the earnings report the stock price went down -35.327%.
Which hedge fund is a major shareholder of Sensus Healthcare, Inc.?
Among the largest hedge funds holding Sensus Healthcare, Inc.’s share is Sheaff Brock Investment Advisors LLC. It holds Sensus Healthcare, Inc.’s shares valued at 0.
Sensus Healthcare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.10 (107.60% Upside)
$7.10 (107.60% Upside)
Blogger Sentiment
Bullish
SRTS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 40.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.81%
12-Months-Change
Fundamentals
Return on Equity
-1.62%
Trailing 12-Months
Asset Growth
1.18%
Trailing 12-Months
Company Description
Sensus Healthcare, Inc.
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
SRTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were significant advancements in international expansion, FDA treatment volume, and potential reimbursement improvements, these were overshadowed by declines in revenue, gross profit, and increased operating expenses. The proposed LCD has also created uncertainty, affecting domestic sales momentum.View all SRTS earnings summariesSRTS Stock 12 Month Forecast
Average Price Target
$7.10
▲(107.60% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
8.82% Mutual Funds
4.47% Other Institutional Investors
78.82% Public Companies and
Individual Investors